Graphite Bio Secures $45M Series A To Advance Targeted Gene Editing Therapy

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Attralus Secures $25M Series A to Diagnose and Treat Amyloidosis
Beyond AAV: AVROBIO and Orchard Take Ex Vivo Approach to Gene Therapy
Generation Bio Blazes New Trail in Gene Therapy with Non-Viral Approach
Versant Ventures Wagers $35M on Cytokine Engineering with Bright Peak